Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Feb 27, 2024 Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA Feb 21, 2024 Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance Feb 20, 2024 Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action Feb 15, 2024 Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer Feb 06, 2024 Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update Jan 24, 2024 Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA Jan 23, 2024 Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application Jan 02, 2024 Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA Dec 21, 2023 Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement Dec 13, 2023 Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 31 - 40 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Feb 27, 2024 Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
Feb 21, 2024 Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
Feb 20, 2024 Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
Feb 15, 2024 Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Feb 06, 2024 Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Jan 24, 2024 Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
Jan 23, 2024 Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
Jan 02, 2024 Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
Dec 21, 2023 Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
Dec 13, 2023 Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
